A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Springer Nature AG & Co. KGaA, together with its subsidiaries, engages in the publishing business in Germany, the United Kingdom, the United States, and internationally. The company operates through three segments: Research, Education, and Health. It offers journals across various academic disciplines under the Nature Portfolio and Springer brand names; books in print and digital formats across various scientific disciplines, including monographs, textbooks, conference proceedings, handbook series, reference works, and briefs under the Springer and Palgrave Macmillan brand names; and support services to researchers, institutions, and industry professionals with AI-powered tools and services, such as AdisInsight, Springer Nature Experiments, protocols.io, and SpringerMaterials, as well as professional development and career services under the Nature Masterclasses, Nature Careers, and Nature Conferences brand names. The company also provides English language teaching content and national curricula learning resources under the Macmillan Education brand name. In addition, it offers specialist information and services to healthcare professionals under the Springer Medizin brand name; publications, learning solutions, and professional services to healthcare practitioners and students under the BSL brand name; content and services related to drug treatments, medical devices, and diagnostics under the Springer Health+ brand name; and Cureus Journal of Medical Science, a peer-reviewed OA medical journal. The company was founded in 1842 and is based in Berlin, Germany. Springer Nature AG & Co. KGaA operates as a subsidiary of GvH Vermögensverwaltungsgesellschaft Xxxiii mbH.
Financial Summary
| Share Statistics | SPGNY | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $4,532.5 | $491.1 | 65% |
|
| Shares Out (Mil) | 227.5 | 43.0 | 79% |
|
| Institutional Ownership | 50.0% | 50.0% | 30% |
|
| Float (Mil) | 26.7 | 33.5 | 34% |
|
| Beta | na | 0.91 | na |
|
| Avg Daily Volume (000s) | 0 | 150 | 0% |
|
| Price Change (52-week) |
na | 68.6% | na |
|
| Growth | SPGNY | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 2.6% | 2.7% | 26% |
|
| Net Income (5yr) | 66.4% | (4.8%) | 97% |
|
| EPS (5yr) | 64.9% | 9.6% | 97 |
|
| Dividends (5yr) | 0.0% | 0.0% | 78% |
|
| Cash Flow (5yr) | (17.1%) | (16.3%) | 41% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | SPGNY | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $2,234 | $599 | 62% |
|
| Net Income (TTM) (Mil) | $374 | ($2) | 75% |
|
| EPS (TTM) | $1.882 | ($0.100) | 70% |
|
| Operating Cash Flow (TTM) (Mil) | $664 | $57 | 75% |
|
| Net Cash Flow (TTM) (Mil) | ($35) | ($2) | 22% |
|
| Long-Term Debt (Q1) (Mil) | $1,615 | $170 | 71% |
|
| Enterprise Value (Q1) (Mil) | $5,873 | $856 | 65% |
|
| Valuation | SPGNY | Industry Median |
Percentile (All Stocks) |
|
| P/B | na | 1.49 | na |
|
| P/E | na | 22.6 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 0.7 | na |
|
| Ratios | SPGNY | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 87.0% | 42.0% | 92% |
|
| Net Margin | 16.8% | (0.9%) | 75% |
|
| ROA | 6.4% | (0.9%) | 77% |
|
| ROE | 16.9% | 0.2% | 75% |
|
| Liabilities to Assets | 60.3% | 59.5% | 54% |
|
| F-Score | na | 4 | na |
|
Springer Nature AG & Co. KGaA did not pass any screens on 9/2/2026.